We use cookies to offer you the best possible service, analyze use of our website and provide access to social media features. For details see our Privacy Rights page.



Can Spravato work with comorbid conditions?

Can Spravato work with comorbid conditions?

Many psychiatric conditions come with what are known as comorbid conditions. These associated conditions affect the primary condition and treating them can be as essential as treating the core condition a patient has.Patients who are interested in Spravato® for the transformative effect it can have on depressive conditions may also wonder what impact it has on comorbid conditions associated with depression. Can Spravato work on these related conditions? Research is ongoing, but early results are proving positive.

What are comorbid conditions?

What is a comorbid condition and how does it impact a person in a psychiatric setting? A comorbid condition is one that occurs at the same time as another in a patient. There are certain conditions that are often comorbid. For example, people diagnosed with depression often may have an anxiety condition as a comorbid condition. Other psychiatric diagnoses may also have an accompanying comorbid physical condition. As an example, a veteran with post-traumatic stress condition, or PTSD, might also have a physical condition such as a traumatic brain injury (TBI) that directly impacts and interacts with their psychiatric condition. For this reason, psychiatrists must always factor in comorbidities when assessing and treating mental health conditions.

What Spravato is Approved to Treat

Research into the efficacy and impact of Spravato on several conditions continues. Currently, Spravato is approved by the FDA for the treatment of major depressive disorder with the presence of suicidal thoughts or behaviors, as well as for treatment-resistant depression. It is the only approved medication by the FDA that can have a positive effect on symptoms within 24 hours, potentially making it an important form of intervention in emergency situations and giving psychiatrists time to develop a more comprehensive treatment plan for depression. Janssen Pharmaceuticals, the manufacturer of Spravato, is continuing to look at its applications as a treatment for common comorbidities.

Conditions that Spravato Is Not Approved to Treat

Spravato is not approved to treat intellectual disability (ID), autism spectrum disorder (ASD), obsessive compulsive disorder (OCD), or social anxiety disorder. Spravato also has not been formally evaluated in patients with comorbid conditions often associated with treatment-resistant depression (TRD), including anxiety conditions (i.e., generalized anxiety disorder, panic attacks, agoraphobia, social anxiety disorder), or post-traumatic stress disorder(PTSD).

Cautions with Other Medications

Spravato may have serious and even harmful effects when used in tandem with certain medications. Spravato should not be used with either memantine or other NMDA antagonists, which work in the same location as Spravato in the brain. People who believe they may have taken either of these medications with Spravato should contact a medical professional as soon as possible. Medications that increase blood pressure, including stimulants such as Adderall and decongestants, can increase the risk of blood pressure rising dangerously high immediately after administration. Additionally, benzodiazepines taken while under treatment with Spravato have been shown to potentially reduce response. Spravato has had a positive impact on many patients experiencing symptoms of depression. While research is ongoing, this powerful medication may yet serve as a form of intervention for depression’s many comorbid conditions. Until that day, people can continue to explore a number of interventions in the treatment of their comorbid conditions by working in consultation with their doctors. If you would like to learn more about comorbid conditions and Spravato, get in touch with one of Andala’s medical professionals today to explore your options.